## UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.	690022.527C4			
First Inventor	Scott S. Graves			
Title	HUMANIZED ANTIBODIES THAT BIND TO THE ANTIGEN BOUND BY ANTIBODY NR-LU-13 AND THEIR USE IN PRETARGETING METHODS			
Express Mail Label No.	EV336652109US			

APPLICATION ELEMENTS ADDI	ADDRESS TO:  Mail Stop Patent Application Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450					
See MPEP chapter 600 concerning utility patent application contents.	Alexandria, VA 22313-1450 5					
1. Fee Transmittal Form (e.g., PTO/SB/17)  (Submit an original and a duplicate for fee processing)	CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)					
2. Applicant claims small entity status. 8. See 37 CFR 1.27.						
3. Specification [Total Pages 74] a. (preferred arrangement set forth below) b.  - Descriptive title of the Invention  - Cross Reference to Related Applications  - Statement Regarding Fed sponsored R & D c.	Specification Sequence Listing on:  i. CD-ROM or CD-R (2 copies); or  ii. Paper  Statements verifying identity of above copies					
- Reference to sequence listing, a table, or a computer program listing appendix - Background of the Invention - Brief Summary of the Invention - Brief Description of the Drawings ( if filed) - Detailed Description - Claim(s) - Abstract of the Disclosure  4. ☑ Drawing(s) (35 U.S.C. 113) [Total Sheets 35] 5. Supplemental Declaration [Total Sheets 10] a. ☐ Newly executed (original or copy) b. ☒ Copy from a prior application (37 CFR 1.63 (d)) (for a continuation/divisional with Box 18 completed) i. ☐ DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).  6. ☒ Application Data Sheet. See 37 CFR 1.76	ACCOMPANYING APPLICATION PARTS  9. Assignment Papers (cover sheet & document(s))  10. 37 CFR 3.73(b) Statement Power of (when there is an assignee) Attorney  11. English Translation Document (if applicable)  12. Information Disclosure Copies of IDS Statement (IDS)/PTO-1449 Citations  13. Preliminary Amendment  14. Return Receipt Postcard (MPEP 503) (Should be specifically itemized)  15. Certified Copy of Priority Document(s) (if foreign priority is claimed)  16. Nonpublication Request under 35 U.S.C. 122(b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.					
18 If a CONTINUING APPLICATION OF APPLICATION CLAIMING FOREIGH	Copy of Ext. of Time Petition for parent appln.					
18. If a CONTINUING APPLICATION OR APPLICATION CLAIMING FOREIGN PRIORITY, check appropriate box, and supply the requisite information below and in the first sentence of the specification following the title, or in an Application Data Sheet under 37 CFR 1.76:  Continuation □ Divisional □ Continuation-in-part (CIP) □ Claims priority from U.S. Patent Application No. 10/056,794 filed 01/24/02  Prior application information						
Correspondence address below	or:					
Firm Name	Customer Number					
Address						
City, State, Zip	00500					
Country (205) 522 4000	2) 602 6024					
Name (Print/Type) Richard G. Sharkey, Ph.D. Regi	istration No. 32,629					
(Allo	orney/Agent)					
Signature Rules Date	February 25, 2004  Millicents/459302					

ETITION EOD	EVTENCION O	F TIME UNDER	27	OFD 4.400/-\
EIIIIUN FUR	EXIENSIUN U	r lime under	3/	CFR 1.136(a)

Docket Number 690022.527C2

	<u> </u>					
In re Application of Scott S. Graves, John M. Reno, Robert W. Mallett, Mark D. Hylarides, Stephen M.J. Searle, Andrew H. Henry, Jan T. Pedersen and Anthony R. Rees						
	Application Number 10/056,794		Filed January 24, 2002			
	For A METHOD OF REDUCING IMMUNOGENICITY OR TOXICITY OF AN ANTIBODY OF IgG CLASS (AS AMENDED					
	Art Unit <b>1642</b>	Examiner BLANCHARD, Dav	vid J.			
This is a request unde reply in the above ider	r the provisions of 37 CFR 1. utified application.	136(a) to extend the po	eriod for filing a			
The requested extensi (check time period des	on and appropriate non-sma	ll-entity fee are as follo	ws			
One mo	onth (37 CFR 1.17(a)(1))		\$			
	onths (37 CFR 1.17(a)(2))		\$			
▼ Three n						
Four months (37 CFR 1.17(a)(4))			\$			
Five mo	onths (37 CFR 1.17(a)(5))		\$			
A check in the Payment by cr The Director h application to a	eed by one-half, and the resulamount of the fee is enclose edit card. Form PTO-2038 is as already been authorized to Deposit Account. The hereby authorized to charge overpayment, to Deposit Account.	d. s attached. o charge fees in this e any fees which may b	pe required			
I am the [] applicant/in	ventor.					
5	record of the entire interest.	See 37 CFR 3.71				
	Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).					
X attorney or	agent of record. Registrati	on No. <u>32,629</u>				
attomey or agent under 37 CFR 1.34(a).						
Registra	tion number if acting under 37 CFR 1	.34(a)				
WARNING: Information be included on this	ion on this form may beco form.  Provide credit card i	me public. Credit car information and author	d information should not orization on PTO-2038.			
2/25/0	ц	trans	Merly			
' Date		Si	gnature <sup>0</sup>			
206-622-4900 Richard G. Sharkey, Ph.D						
Telephone Nur			or printed name neir representative(s) are required.			
Submit multiple forms if more	than one signature is required,	see below*.	ien representative(s) are required.			

Oz,

MillicentS/459048